| | | | | | Präparat | Packungsgrösse | EFP | PP | SB | TK | Zusammensetzung | Zulassungsinhaber | Kat. | | | | |
|---|
|
| | | FI | PI | | Madopar 62.5 - T | 100 Capsule(s) | 8.48 | 18.30 | 10% | | Capsules: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G |  |
| | | FI | PI | | Madopar 125 | 100 Capsule(s) | 11.01 | 28.35 | 10% | | Capsules: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | FI | PI | | Madopar 125 - T | 30 Tablet(s) | 3.90 | 13.45 | 10% | | Tablets: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | FI | PI | | Madopar 125 - T | 100 Tablet(s) | 11.01 | 28.35 | 10% | | Tablets: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | FI | PI | | Madopar 250 - T | 30 Tablet(s) | 8.76 | 18.60 | 10% | | Tablets: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | FI | PI | | Madopar 250 - T | 100 Tablet(s) | 26.64 | 44.90 | 10% | | Tablets: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL / SO | FB | | G | |
| | | FI | PI | | Carbidopa/Levodopa Sandoz CR
25/100 - T | 30 Tablet(s) | 4.59 | 14.25 | 10% | | Delayed release tablets: 2 Wirkstoffe | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | FI | PI | | Carbidopa/Levodopa Sandoz CR
25/100 - T | 100 Tablet(s) | 12.94 | 30.50 | 10% | | Delayed release tablets: 2 Wirkstoffe | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | FI | PI | | Carbidopa/Levodopa Sandoz CR
50/200 - T | 30 Tablet(s) | 8.52 | 25.70 | 10% | | Delayed release tablets: 2 Wirkstoffe | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | FI | PI | | Carbidopa/Levodopa Sandoz CR
50/200 - T | 100 Tablet(s) | 26.51 | 45.25 | 10% | | Delayed release tablets: 2 Wirkstoffe | Sandoz
Pharmaceuticals AG | B / SL / SG | FB | | G | |
| | | FI | PI | | Levodopa / Benserazid
Devatis 62.5 mg (50 mg +
12.5 mg) | 100 | 5.94 | 15.70 | 10% | | Tablets: 2 Wirkstoffe | Devatis AG | B / SL / SG | FB | | G | |
| | | FI | | | Levodopa / Benserazid
Devatis 125 mg (100 mg + 25 mg) | 30 | 3.55 | 13.10 | 10% | | Tablets: 2 Wirkstoffe | Devatis AG | B / SL / SG | FB | | G | |
| | | FI | | | Levodopa / Benserazid
Devatis 125 mg (100 mg + 25 mg) | 100 | 10.01 | 27.30 | 10% | | Tablets: 2 Wirkstoffe | Devatis AG | B / SL / SG | FB | | G | |
| | | FI | | | Levodopa / Benserazid
Devatis 250 mg (200 mg + 50 mg) | 30 | 6.13 | 15.90 | 10% | | Tablets: 2 Wirkstoffe | Devatis AG | B / SL / SG | FB | | G | |
| | | FI | | | Levodopa / Benserazid
Devatis 250 mg (200 mg + 50 mg) | 100 | 18.65 | 36.70 | 10% | | Tablets: 2 Wirkstoffe | Devatis AG | B / SL / SG | FB | | G | |
| | | FI | PI | | Madopar DR | 30 Tablet(s) | 17.19 | 35.10 | 10% | | Tablets: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | FI | PI | | Madopar DR | 100 Tablet(s) | 53.64 | 74.75 | 10% | | Tablets: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | FI | PI | | Sinemet 25/100 mg | 30 | 5.23 | 14.90 | 10% | | Tablets: 2 Wirkstoffe | Organon GmbH | B / SL | FB | | G | |
| | | FI | PI | | Sinemet 25/100 mg | 100 | 15.02 | 32.75 | 10% | | Tablets: 2 Wirkstoffe | Organon GmbH | B / SL | FB | | G | |
| | | FI | PI | | Sinemet 25/250 mg | 30 | 7.19 | 17.05 | 10% | | Tablets: 2 Wirkstoffe | Organon GmbH | B / SL | FB | | G | |
| | | FI | PI | | Sinemet 25/250 mg | 100 | 22.43 | 40.80 | 10% | | Tablets: 2 Wirkstoffe | Organon GmbH | B / SL | FB | | G | |
| L | | FI | PI | | Duodopa | 7 Sachet(s) | 405.36 | 457.25 | 10% | | Gel for intestinal application: 2 Wirkstoffe | AbbVie AG | B / SL | FB | | G | |
| | | FI | PI | | Madopar LIQ 62.5 | 100 Tablet(s) | 8.48 | 25.65 | 10% | | Tabletten zur Herstellung einer Suspension zum Einnehmen: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | FI | PI | | Madopar LIQ 125 - T | 30 Tablet(s) | 5.07 | 14.75 | 10% | | Tabletten zur Herstellung einer Suspension zum Einnehmen: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | FI | PI | | Madopar LIQ 125 - T | 100 Tablet(s) | 14.30 | 31.95 | 10% | | Tabletten zur Herstellung einer Suspension zum Einnehmen: 2 Wirkstoffe | Roche Pharma
(Schweiz) AG | B / SL | FB | | G | |
| | | FI | PI | | Levacin 100/25 | 30 | PA | PA | k.A. | | Delayed release tablets: 2 Wirkstoffe | Acino Pharma AG | B | FB | | G | |
| | | FI | PI | | Levacin 100/25 | 100 | PA | PA | k.A. | | Delayed release tablets: 2 Wirkstoffe | Acino Pharma AG | B | FB | | G | |
| | | FI | PI | | Levacin 200/50 | 30 | PA | PA | k.A. | | Delayed release tablets: 2 Wirkstoffe | Acino Pharma AG | B | FB | | G | |
| | | FI | PI | | Levacin 200/50 | 100 | PA | PA | k.A. | | Delayed release tablets: 2 Wirkstoffe | Acino Pharma AG | B | FB | | G | |
| | | FI | PI | | Levodopa / Benserazid
Devatis 62.5 mg (50 mg +
12.5 mg) | 30 | 1.78 | 6.65 | k.A. | | Tablets: 2 Wirkstoffe | Devatis AG | B | FB | | G | |
